Evidence map›Paper›PMID 22936355›Full record

ReviewAmerican journal of respiratory and critical care medicine2012

The next generation of complex lung genetic studies.

Ivana V Yang, David A Schwartz

Abstract readReview
In one paragraph

Review in American journal of respiratory and critical care medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Inherited lung cancer: a review.Ecancermedicalscience · 2020
    Review
  3. Article
  4. Article
  5. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.American journal of respiratory and critical care medicine · 2014
    Article
  6. Genetic testing in diffuse parenchymal lung disease.Orphanet journal of rare diseases · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ivana V YangDepartment of Medicine, University of Colorado Denver, 12700 East 19th Avenue, 8611, Aurora, CO 80045, USA. ivana.yang@ucdenver.edu
David A Schwartz

Funding

Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)R01HL097163 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI FINGERLIN, TASHA E., SCHWARTZ, DAVID ALBERT · 2009 to 2018
$16.4M
Lung Genomics Research ConsortiumRC2HL101715 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI GERACI, MARK W, KAMINSKI, NAFTALI · 2009 to 2010
$11.4M
Genomic Signatures for Idiopathic Interstitial PneumoniaR01HL095393 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2008 to 2011
$3.3M
Genetic and Epigenetic Changes in MUC5B and Fibrosing Interstitial Lung DiseaseI01BX001534 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI SCHWARTZ, DAVID ALBERT · 2013 to 2016
–
BLRD VA I01 BX001534NHLBI NIH HHS R01 HL095393NHLBI NIH HHS R01-HL095393NHLBI NIH HHS R01 HL097163NHLBI NIH HHS R01-HL097163NHLBI NIH HHS RC2 HL101715NHLBI NIH HHS RC2-HL101715
6 · The paper itself

Abstract

Common genetic risk variants identified by genome-wide association studies have explained a small portion of disease heritability in complex diseases. It is becoming apparent that each gene/locus is heterogeneous and that multiple rare independent risk alleles across the population contribute to disease risk. Next-generation sequencing technologies have reached the maturity and low cost necessary to perform whole genome, whole exome, and targeted region sequencing to identify all rare risk alleles across a population, a task that is not possible to achieve by genotyping. Design of whole genome, whole exome, and targeted sequencing projects to identify disease variants for complex lung diseases requires four main steps: library preparation, sequencing, sequence data analysis, and statistical analysis. Although data analysis approaches are still evolving, a number of published studies have successfully identified rare variants associated with complex disease. Despite many challenges that lie ahead in applying these technologies to lung disease, rare variants are likely to be a critical piece of the puzzle that needs to be solved to understand the genetic basis of complex lung disease and to use this information to develop better therapies.

Indexed as

Genetic Predisposition to DiseaseGenome-Wide Association StudySequence Analysis, DNAFemaleGenetic VariationGenome, HumanHumansLung DiseasesMaleRisk AssessmentUnited States

Identifiers

PMID22936355
PMCPMC3530203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.